The rise in nosocomial infections caused by multidrug-resistant pathogens is a major public health problem
background
A new strategy for dealing with antibiotic-resistant pathogens is to vaccinate
The strategy has been successfully applied to methicillin-resistant Staphylococcus aureus and P.
Summary of the study
The authors evaluated a macrophage-coated nanotoxoid (MΦ-NT) vaccine that generates immunity
Research highlights
MΦ-NT can cause rapid, long-lasting immunity: MΦ-NT
Single-dose post-immunization analysis of rapidly produced antibodies in mouse models of pneumonia has a protective effect: at different times after vaccination in mouse models, Pseudomonas aeruginosa is given in the trachea to induce pneumonia, and the bacterial load
CP-induced immunodeficiency mouse model of leukopenia, increasing susceptibility to bacterial infections
To assess the clinical relevance of MΦ-NT in high-risk populations, an animal model
Immunoprotective effect of subcutaneous inoculation and intranasal inoculation of MΦ-NT on immunodeficient mice
After confirming that CP therapy increases susceptibility to bacterial infections, the benefits
In addition, the vaccine's protection against
Transnasal inoculation of MΦ-NT is effective in inducing high IgG antibody titers, although lower than subcutaneous inoculation
Passive transfer of immune serum reduces the bacterial load
In models of pneumonia and sepsis, the protective mechanism by which MΦ-NT is effective against infection may be due to high antibody titers, suggesting that humoral immunity may play a major role
Neutrophils mediate the clearance of bacteria from immunocompromised mice
While antibodies can recognize and regulate pathogens, these proteins by themselves do not eradicate bacteria
Inoculation with MΦ-NT has a protective effect on infection in elderly mice
In addition to hospitalized patients, another group at high risk of serious infection is the elderly, because immune function declines
MΦ-NT prepared with human cell membranes has good anti-Pseudomonas aeruginosa action
In clinical applications, MΦ-NT should be manufactured using plasma membranes derived from human cells to minimize adverse cross-species immune responses
discuss
This nano-vaccine quickly triggers a strong antibacterial immunity that lasts for at least 4 months
